Global Methicillin-resistant Staphylococcus Aureus Drugs Market Overview
Methicillin-resistant Staphylococcus Aureus Drugs Market Size was valued at USD 3.32 Billion in 2023. The Global MRSA Drugs industry is projected to grow from USD 3.45 Billion in 2024 to USD 4.68 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.10% during the forecast period (2024 - 2032).
Some of the major market drivers propelling the Methicillin-resistant Staphylococcus Aureus Drugs market are the increasing number of clinical trials, the growing incidence of antibiotic-resistant strains, and the ongoing exposure to multidrug-resistant organisms in healthcare facilities as a result of prolonged hospital stays.
April 2024: Zevtera (ceftobiprole) from Basilea has been approved by the FDA for the treatment of three distinct types of infections. The nods will be beneficial to patients who have developed resistance to the current stock of antibiotics available in the United States, the majority of which have been on the market for decades. Adults with acute bacterial skin and skin structure infections (ABSSSI) and adults with staphylococcus aureus bacteremia (SAB), a systemic infection that can be fatal, may be administered Zevtera.
It is also effective in the treatment of community-acquired bacterial pneumonia (CABP) in patients aged three months and older. The approvals will grant Basilea a 10-year exclusivity period in the United States for Zevtera, as it was designated as a Qualified Infectious Disease Product under the Generate Antibiotics Incentives Now Act. Basilea anticipates that it will be possible to secure a partner to market Zevtera in the United States by the "middle of this year." The collaborator will be responsible for determining the price of the product.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Methicillin-resistant Staphylococcus Aureus Drugs Market Trends
-
Rise in the prevalence of methicillin-resistant infections is driving the market growth
The market for methicillin-resistant Staphylococcus aureus medications is anticipated to develop in the future due to the rise in the prevalence of methicillin-resistant infections. Methicillin-resistant Staphylococcus aureus (MRSA), which produce infections of the kind that are not responsive to the prescription of at least one of antibiotics, are bacteria which are responsible for MRSA infections. ARBs that intend to kill and make the growth of MRSA bacteria among the mammals and humans are the primary ARBs that have to be administered in the MRSA treatment plan. This could be visualized by Center for Disease Control and Prevention and Prevention or CDC and P, a health agency under the Department of Health and Human Services that reported in November 2022 that hospital acquired Methicillin-resistant S aureus or MRSA infections had increased by 14% in the year. Moreover, the General Institute of Public Health in Denmark reported MRSA disease outbreak among its population in December 2022. The data showed 181 cases of community-acquired infections within the last six months with a history of contact with a hospital or nursing home (higher than 159 of 2020). Consequently a niche market for MRSA drug therapy has emerged with more people affected by such superbug infections reported.
In addition, due to growing aging population, the market of MRSA drugs is expected to grow in the future years. Those who are 65 and over fall into the older people category. To obtain the percentage of dependent population, the number of old and young people is divided into the number of the rest of the population evaluated as a percentage of the total number of people. Consequently, the elderly with weakened immune systems had a tendency of having infections like MRSA. Age causes poor immunity, therefore, the immune system is not the one that it once was and makes them more susceptible to MRSA. A case in point is the UN that forecasts that by October 2022 this group will be one sixth of the global population. This will be the time when the world population would have risen to the 1 billion mark. It will be believed that by 2050 there will be about 1. The UN predicts 5 billion extra older persons over 60 years, versus 1 billion now. An individual 60 years old or above shall be doubled (ii. e. , 2. A number and volume of 33 billion people will be living in the world by 2050. It is predicted that population of 80 years and above will be tripled in the subsequent 30 years and would come to 426 million. Therefore, MRSA drugs are becoming more preferable as the increasing infections among the older number. Thus, driving the Methicillin-resistant Staphylococcus Aureus Drugs market revenue.
Methicillin-resistant Staphylococcus Aureus Drugs Market Segment Insights
Methicillin-resistant Staphylococcus Aureus Drugs Dug Class Insights
The Methicillin-resistant Staphylococcus Aureus Drugs Market segmentation, based on drug class, includes Lipopeptides, Oxazolidinones, Cephalosporin, Tetracycline, Folate Antagonist, and Other Drug Classes. In 2023, the lipopeptides segment dominated the market due to the well-established market for lipopeptides, including Daptomycin, and the effective global distribution provided by producers and distributors.
Methicillin-resistant Staphylococcus Aureus Drugs Route of Administration Insights
The Methicillin-resistant Staphylococcus Aureus Drugs Market segmentation, based on route of administration, includes Oral Administration and Parenteral Administration. The parenteral administration category generated the most income in 2023 as it is the shortest method of administering medication during the initial course of treatment. This makes it possible to give patients their medication quickly and help them feel better. This enhances the drug's action and gives the patient first-line therapy.
Figure 1: Methicillin-resistant Staphylococcus Aureus Drugs Market, by Route of Administration, 2023 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Methicillin-resistant Staphylococcus Aureus Drugs Distribution Channel Insights
The Methicillin-resistant Staphylococcus Aureus Drugs Market segmentation, based on distribution channel, includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The hospital pharmacies category generated the most income in 2023. The primary drivers of the hospital pharmacy segment's dominance in terms of revenue are the growing number of multispecialty hospitals around the world and the better availability of generic MRSA medications in hospital pharmacies worldwide.
Methicillin-resistant Staphylococcus Aureus Drugs Regional Insights
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Methicillin-resistant Staphylococcus Aureus Drugs market area will dominate this market. North America is predicted to remain dominant in the forecast period due to the strategic presence of important antibiotic manufacturing businesses in the U.S. This is because major players are investing more in the R&D of innovative medication molecules against MRSA infection.
Further, the major countries studied in the market report are the US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, and South Korea.
Figure 2: Methicillin-Resistant Staphylococcus Aureus Drugs Market Share By Region 2023 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Methicillin-resistant Staphylococcus Aureus Drugs market accounts for the second-largest market share because of research grants to encourage the development of anti-MRSA medications from European governments and private companies. In addition, the UK government is working hard to stop surgical site infections (SSIs) from happening there. Thus, market expansion in Europe is being driven by the government's enhanced efforts and preventive measures for the reduction of surgical site infections. Further, the German Methicillin-resistant Staphylococcus Aureus Drugs market held the largest market share, and the UK Methicillin-resistant Staphylococcus Aureus Drugs market was the fastest growing market in the European region.
The Asia-Pacific Methicillin-resistant Staphylococcus Aureus Drugs Market is expected to grow at the fastest CAGR from 2024 to 2032. The increasing rate of MRSA infections and the improved healthcare system in the area are the main drivers of the market expansion. Furthermore, the public health agencies' and the government's increased assistance in treating MRSA infections in individuals is anticipated to drive target market expansion. Moreover, China’s Methicillin-resistant Staphylococcus Aureus Drugs market held the largest market share, and the Indian Methicillin-resistant Staphylococcus Aureus Drugs market was the fastest growing market in the Asia-Pacific region.
Methicillin-resistant Staphylococcus Aureus Drugs Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Methicillin-resistant Staphylococcus Aureus Drugs market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Methicillin-resistant Staphylococcus Aureus Drugs industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Methicillin-resistant Staphylococcus Aureus Drugs industry to benefit clients and increase the market sector. In recent years, the Methicillin-resistant Staphylococcus Aureus Drugs industry has offered some of the most significant advantages to medicine. Major players in the Methicillin-resistant Staphylococcus Aureus Drugs market are attempting to increase market demand by investing in research and development operations includes Teva Pharmaceutical Industries ltd, Cumberland Pharmaceuticals Inc, AbbVie Inc., Merck & Co Inc, Pfizer Inc, Theravance Biopharma, Basilea Pharmaceutica, AmpliPhi Biosciences Corporation, Debiopharm International S.A., Nabriva Therapeutics Plc, Melinta Therapeutics Inc, Innovation Pharmaceuticals Inc., and Paratek Pharmaceuticals, Inc.
The biopharmaceutical business Melinta Therapeutics, LLC (Melinta) is dedicated to the discovery of innovative anti-infectives for the treatment of diverse bacterial illnesses. Antibiotics are part of its marketed portfolio and are used to treat severe bacterial infections, such as complicated urinary tract infections (cUTI) and acute bacterial skin and skin structure infections (ABSSSI), as well as to prevent and treat other serious infections caused by susceptible bacteria. A startup in the commercial stage, Melinta Therapeutics (Melinta) creates innovative remedies for acute and critical illnesses. The lipoglycopeptide antibiotic KIMYRSA (oritavancin), which totally resolves acute bacterial skin and skin structure infections (ABSSSI) with a single, one-hour infusion of 1,200 mg, was recently introduced for commercial use, according to the firm.
Specializing in the acquisition, development, and marketing of branded prescription medications, Cumberland Pharmaceuticals Inc. (Cumberland) is a pharmaceutical firm. Gastroenterology, cancer supportive care, and acute care in hospitals are its main target markets. With the help of its US hospital and gastrointestinal sales teams, Cumberland Pharma advertises approved medications. Additionally, the business is building a global network of partners to sell its goods in other nations. Nashville, Tennessee, in the United States, is home to Cumberland Pharma's headquarters.
Key Companies in the Methicillin-resistant Staphylococcus Aureus Drugs market include
- Teva Pharmaceutical Industries ltd
- Cumberland Pharmaceuticals Inc
- AbbVie Inc.
- Merck & Co Inc
- Pfizer Inc
- Theravance Biopharma
- Basilea Pharmaceutica
- AmpliPhi Biosciences Corporation
- Debiopharm International S.A.
- Nabriva Therapeutics Plc
- Melinta Therapeutics Inc
- Innovation Pharmaceuticals Inc.
- Paratek Pharmaceuticals, Inc.
Methicillin-resistant Staphylococcus Aureus Drugs Industry Developments
May 2023: The company Roche Information Solutions India Pvt Ltd, which creates cutting-edge solutions to support labs and physicians, has announced that it will be exhibiting cutting-edge digital diagnostics and laboratory solutions under the theme "Innovation Past, Present, and Future" at WorldLab-EuroMedLab 2023, which will take place in Rome, Italy, from May 21–25. Attendees get the chance to see firsthand the most recent technical innovations from Roche in point of care, molecular, lab automation, and serum workspace.
July 2021: KIMYRSA (oritavancin), a lipoglycopeptide antibiotic developed by Melinta Therapeutics, provides a comprehensive course of treatment for acute bacterial skin and skin structure infections (ABSSSI) brought on by susceptible isolates of specific Gram-positive microorganisms, such as methicillin-resistant Staphylococcus aureus (MRSA).
Methicillin-resistant Staphylococcus Aureus Drugs Market Segmentation
Methicillin-resistant Staphylococcus Aureus Drugs Drug Class Outlook
- Lipopeptides
- Oxazolidinones
- Cephalosporin
- Tetracycline
- Folate Antagonist
- Other Drug Classes
Methicillin-resistant Staphylococcus Aureus Drugs Route of Administration Outlook
- Oral Administration
- Parenteral Administration
Methicillin-resistant Staphylococcus Aureus Drugs Distribution Channel Outlook
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Methicillin-resistant Staphylococcus Aureus Drugs Regional Outlook
- North America
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- Rest of the World
- Middle East
- Africa
- Latin America
|
Report Attribute/Metric
|
Details
|
|
Market Size 2023
|
USD 3.32 Billion
|
|
Market Size 2024
|
USD 3.45 Billion
|
|
Market Size 2032
|
USD 4.68 Billion
|
|
Compound Annual Growth Rate (CAGR)
|
4.10% (2024-2032)
|
|
Base Year
|
2023
|
|
Market Forecast Period
|
2024-2032
|
|
Historical Data
|
2019-2022
|
|
Market Forecast Units
|
Value (USD Billion)
|
|
Report Coverage
|
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
|
|
Segments Covered
|
Drug Class, Route of Administration, Distribution Channel, and Region
|
|
Geographies Covered
|
North America, Europe, Asia Pacific, and the Rest of the World
|
|
Countries Covered
|
The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea
|
|
Key Companies Profiled
|
Teva Pharmaceutical Industries ltd, Cumberland Pharmaceuticals Inc, AbbVie Inc., Merck & Co Inc, Pfizer Inc, Theravance Biopharma, Basilea Pharmaceutica, AmpliPhi Biosciences Corporation, Debiopharm International S.A., Nabriva Therapeutics Plc, Melinta Therapeutics Inc, Innovation Pharmaceuticals Inc., and Paratek Pharmaceuticals, Inc.
|
|
Key Market Opportunities
|
· Increased Government Initiative Support and Research Activities by Major Players to Develop Novel MRSA Drugs
|
|
Key Market Dynamics
|
· Rising Worldwide Infection Rates and Need for Innovative Treatments
· Increasing Knowledge of Bacterial Infection
|
MRSA Drugs Market Highlights:
Frequently Asked Questions (FAQ) :
The Methicillin-resistant Staphylococcus Aureus Drugs Market size was valued at USD 3.32 Billion in 2023.
The global market is projected to grow at a CAGR of 4.10% during the forecast period, 2024-2032.
North America had the largest share in the global market.
The key players in the market are Teva Pharmaceutical Industries ltd, Cumberland Pharmaceuticals Inc, AbbVie Inc., Merck & Co Inc, Pfizer Inc, Theravance Biopharma, Basilea Pharmaceutica, AmpliPhi Biosciences Corporation, Debiopharm International S.A., Nabriva Therapeutics Plc, Melinta Therapeutics Inc, Innovation Pharmaceuticals Inc., and Paratek Pharmaceuticals, Inc., among others.
The lipopeptides category dominated the market in 2023.
The hospital pharmacies had the largest share in the global market.
